• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DIDANOSINE Drug Record

  • Summary
  • Interactions
  • Claims
  • DIDANOSINE chembl:CHEMBL1460 Approved

    Alternate Names:

    DDI
    DIDANOSINE
    VIDEX EC
    DIDANOSINE SYSTEM SUITABILITY MIXTURE
    DIDEOXYINOSINE (DDI)
    VIDEX
    NSC-612049
    BMY-40900
    DIDEOXYINOSINE
    9-[(2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE
    VIDEX EC®
    DDINO
    2,3-DIDEOXYINOSINE
    9-((2R,5S)-5-(HYDROXYMETHYL)-TETRAHYDROFURAN-2-YL)-1H-PURIN-6(9H)-ONE
    chemidplus:69655-05-6
    drugbank:00900
    pubchem.compound:50599
    chembl:CHEMBL1460
    rxcui:3364

    Drug Info:

    (3 More Sources)

    Publications:

    Vispo E et al., 2013, Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients., Clin Infect Dis
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Zhu et al., 2007, Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression., Brain
    Nokta et al., 1997, Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea., AIDS Res. Hum. Retroviruses
    Reddy et al., 1991, Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI)., J. Clin. Lab. Anal.
  • DIDANOSINE   NT5C2

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23315321


    Sources:
    PharmGKB

  • DIDANOSINE   TNFRSF1B

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9430255


    Sources:
    NCI

  • DIDANOSINE   XDH

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23315321


    Sources:
    PharmGKB

  • DIDANOSINE   IL2RA

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1774603


    Sources:
    NCI

  • DIDANOSINE   BDNF

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17616550


    Sources:
    NCI

  • DIDANOSINE   TNF

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9430255


    Sources:
    NCI

  • DIDANOSINE   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DIDANOSINE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DIDANOSINE   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DIDANOSINE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DIDANOSINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DIDANOSINE   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NCI: DDI

    • Version: 14-September-2017

    Alternate Names:
    C431 NCI drug code

    Drug Info:

    Publications:
    Zhu et al., 2007, Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression., Brain

  • NCI: DIDEOXYINOSINE

    • Version: 14-September-2017

    Alternate Names:
    C431 NCI drug code

    Drug Info:

    Publications:
    Reddy et al., 1991, Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI)., J. Clin. Lab. Anal.

  • NCI: DIDANOSINE

    • Version: 14-September-2017

    Alternate Names:
    C431 NCI drug code

    Drug Info:

    Publications:
    Nokta et al., 1997, Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea., AIDS Res. Hum. Retroviruses

  • DTC: DIDANOSINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1460 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: didanosine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Vispo E et al., 2013, Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients., Clin Infect Dis

  • TTD: Didanosine

    • Version: 2020.06.01

    Alternate Names:
    D06FDR TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1460

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21